11,316 results match your criteria Acute Promyelocytic Leukemia


Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.

PLoS One 2021 7;16(5):e0251011. Epub 2021 May 7.

Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Objective: The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML.

Methods: We retrospectively analyzed 3,011 adult AML patients identified from a nationwide database between January 2007 and December 2011. Read More

View Article and Full-Text PDF

Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Biomark Res 2021 May 6;9(1):33. Epub 2021 May 6.

Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, #79 Qingchun Rd, Zhejiang, 310003, Hangzhou, China.

Acute promyelocytic leukemia (APL) is characterized by the accumulation of promyelocytes in bone marrow. More than 95% of patients with this disease belong to typical APL, which express PML-RARA and are sensitive to differentiation induction therapy containing all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), and they exhibit an excellent clinical outcome. Compared to typical APL, variant APL showed quite different aspects, and how to recognize, diagnose, and treat variant APL remained still challenged at present. Read More

View Article and Full-Text PDF

A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.

Leuk Res 2021 Apr 24;107:106588. Epub 2021 Apr 24.

Section of Leukemia, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Background: Rasburicase can markedly and rapidly decrease uric acid (UA) levels, thereby preventing and treating tumor lysis syndrome. However, rasburicase is expensive, especially when used as per the manufacturer's recommended dosage of 0.2 mg/kg/day for up to 5 days. Read More

View Article and Full-Text PDF

miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT.

J Oncol 2021 16;2021:5522051. Epub 2021 Apr 16.

Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China.

Acute promyelocytic leukemia (APL) patients with progressive leukocytosis are more likely to have various complications and poor outcomes. However, the regulatory roles of microRNAs in the leukocytosis of APL have not been clarified. Our study aims to evaluate the effects of miRNAs on leukocytosis during induction therapy of APL patients and explore its potential mechanisms. Read More

View Article and Full-Text PDF

Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.

Acta Med Okayama 2021 Apr;75(2):219-224

Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor's treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Read More

View Article and Full-Text PDF

Acute myeloid leukaemia presenting with ecthyma gangrenosum as the first manifestation: A case report.

Medicine (Baltimore) 2021 May;100(18):e25867

Department of Emergency Medicine, St. Mary's Hospital, Kurume, Japan.

Rationale: Ecthyma gangrenosum (EG) is an uncommon cutaneous infection usually associated with Pseudomonas aeruginosa bacteremia in immunocompromised patients, particularly those with underlying malignant diseases. Despite its rarity, especially in immunocompetent or nondiagnosed immunodeficiency patients, EG can present as the first manifestation of an underlying immunosuppression.

Patient Concerns: A 42-year-old Japanese man was admitted to our hospital with a 3-day history of a painless red macule on his right forearm and fever. Read More

View Article and Full-Text PDF

Multidisciplinary corroboration in differentiation syndrome: a case report.

J Med Case Rep 2021 May 5;15(1):226. Epub 2021 May 5.

Department of Pediatric ICU, Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, 700160, West Bengal, India.

Background: Differentiation syndrome (DS) is a life-threatening complication that may be seen in patients with acute promyelocytic leukaemia undergoing induction therapy with all-trans retinoic acid or arsenic trioxide. It can lead to severe inflammatory response syndrome and shock if adequate measures are not taken immediately. The radiological features of lung nodules with changes in ground-glass opacity can represent DS. Read More

View Article and Full-Text PDF

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid.

Cancers (Basel) 2021 Apr 29;13(9). Epub 2021 Apr 29.

Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.

All-trans retinoic acid (ATRA) and valproic acid (VP) have been tried in the treatment of non-promyelocytic variants of acute myeloid leukemia (AML). Non-randomized studies suggest that the two drugs can stabilize AML and improve normal peripheral blood cell counts. In this context, we used a proteomic/phosphoproteomic strategy to investigate the in vivo effects of ATRA/VP on human AML cells. Read More

View Article and Full-Text PDF

Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.

Clin Transl Oncol 2021 May 3. Epub 2021 May 3.

The first Affiliated Hospital of Harbin Medical University, Harbin, China.

Purpose: APL patients have recurrent alterations in FLT3, WT1, NRAS and KRAS. Gene mutations have a strong potential for involvement in pathogenesis and may have potential effects on the clinical manifestations. Gene mutations may even be associated with early death (ED) in APL patients. Read More

View Article and Full-Text PDF

Successful treatment of acute promyelocytic leukemia in a patient with prosthetic heart valves: a case report and review of the literature.

J Med Case Rep 2021 May 4;15(1):260. Epub 2021 May 4.

Faghihi Hospital-Shiraz University of Medical Sciences, Shiraz, Iran.

Background: Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are controversial due to the high risk of bleeding caused by disseminated intravascular coagulation (DIC) and thrombocytopenia. To the best of our knowledge we report the first case of APL in a patient with prosthetic heart valves successfully treated with a combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Read More

View Article and Full-Text PDF

Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia.

Front Oncol 2021 15;11:666014. Epub 2021 Apr 15.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Patients with acute promyelocytic leukemia (APL) often present with potentially life-threatening hemorrhagic diathesis. The underlying pathomechanisms of APL-associated coagulopathy are complex. However, two pathways considered to be APL-specific had been identified: 1) annexin A2 (ANXA2)-associated hyperfibrinolysis and 2) podoplanin (PDPN)-mediated platelet activation and aggregation. Read More

View Article and Full-Text PDF

Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all- retinoic acid and arsenic trioxide.

Clin Case Rep 2021 Apr 24;9(4):2192-2195. Epub 2021 Feb 24.

Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran.

Thrombocytosis is an unusual side effect of all- retinoic acid (ATRA) treatment that occurs in some patients with acute promyelocytic leukemia (APL). Read More

View Article and Full-Text PDF

Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.

Clin Lymphoma Myeloma Leuk 2021 Mar 29. Epub 2021 Mar 29.

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address:

Background: Acute myeloid leukemia (AML) is a hematological malignancy originating from myeloid precursor cells, with different cytogenetic abnormalities, genetic mutations and diverse clinical prognoses. We investigated the clinical characteristics, treatment patterns, and outcomes of adult AML patients in Taiwan.

Materials And Methods: We retrospectively included 3851 patients with AML in the Taiwan Cancer Registry Database from 2011 to 2015. Read More

View Article and Full-Text PDF

Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG).

Clin Lymphoma Myeloma Leuk 2021 Mar 20. Epub 2021 Mar 20.

Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.

Background: Acute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of this study was to determine the clinical features and outcomes of Thai patients with AML. Read More

View Article and Full-Text PDF

Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM.

J Clin Med 2021 Apr 13;10(8). Epub 2021 Apr 13.

Dijon-Bourgogne University Hospital, Registre Bourguignon des Cancers Digestifs, F-21000 Dijon, France.

With improvements in acute myeloid leukemia (AML) diagnosis and treatment, more patients are surviving for longer periods. A French population of 9453 AML patients aged ≥15 years diagnosed from 1995 to 2015 was studied to quantify the proportion cured (P), time to cure (TTC) and median survival of patients who are not cured (MedS). Net survival (NS) was estimated using a flexible model adjusted for age and sex in sixteen AML subtypes. Read More

View Article and Full-Text PDF

Ampelopsin Inhibits Cell Proliferation and Induces Apoptosis in HL60 and K562 Leukemia Cells by Downregulating AKT and NF-κB Signaling Pathways.

Int J Mol Sci 2021 Apr 20;22(8). Epub 2021 Apr 20.

Department of Life Science and Biochemical Engineering, Sun Moon University, Asan 31460, Korea.

Leukemia is a type of blood cancer caused by the rapid proliferation of abnormal white blood cells. Currently, several treatment options, including chemotherapy, radiation therapy, and bone marrow transplantation, are used to treat leukemia, but the morbidity and mortality rates of patients with leukemia are still high. Therefore, there is still a need to develop more selective and less toxic drugs for the effective treatment of leukemia. Read More

View Article and Full-Text PDF

ATF3 Promotes Arsenic-Induced Apoptosis and Oppositely Regulates DR5 and Bcl-xL Expression in Human Bronchial Epithelial Cells.

Int J Mol Sci 2021 Apr 19;22(8). Epub 2021 Apr 19.

Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Institute of Engineering Biology and Health, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.

Arsenic is one of the most common environmental pollutants eliciting serious public health issues; however, it is also a well-recognized chemotherapeutic agent for acute promyelocytic leukemia. The association between arsenic exposure and lung diseases has been established, but underlying molecular mechanisms are poorly defined. Here we investigated the toxicology of arsenic in airway epithelium. Read More

View Article and Full-Text PDF

Melatonin as a Potential Multitherapeutic Agent.

J Pers Med 2021 Apr 6;11(4). Epub 2021 Apr 6.

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, 142290 Moscow, Russia.

Melatonin (N-acetyl-5-methoxytryptamine, MEL) is a hormone produced by the pineal gland that was discovered many years ago. The physiological roles of this hormone in the body are varied. The beneficial effects of MEL administration may be related to its influence on mitochondrial physiology. Read More

View Article and Full-Text PDF

Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia.

Drug Des Devel Ther 2021 21;15:1633-1640. Epub 2021 Apr 21.

Department of Pediatric, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.

Background: An oral tetra-arsenic tetra-sulfide (ASS) formula has been recommended as an outpatient post-remission treatment for Chinese adults with acute promyelocytic leukemia (APL) but limited data are available for children. In this exploratory study, we aimed to evaluate the pharmacokinetics and safety of the ASS formula in children.

Methods: Eleven newly diagnosed and one relapsed pediatric patient (4-14 years of age) treated with the ASS formula were included. Read More

View Article and Full-Text PDF

[Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term treatment for chronic myeloid leukemia: a case report].

Zhonghua Xue Ye Xue Za Zhi 2021 Mar;42(3):259

Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.

View Article and Full-Text PDF

(-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1.

Sci Rep 2021 Apr 27;11(1):9103. Epub 2021 Apr 27.

Haematology and Transfusion Medicine Centre - Hemocentro, University of Campinas, Campinas, 13083-878, Brazil.

(-)-Epigallocatechin-3-gallate (EGCG), the major active polyphenol extracted from green tea, has been shown to induce apoptosis and inhibit cell proliferation, cell invasion, angiogenesis and metastasis. Herein, we evaluated the in vivo effects of EGCG in acute myeloid leukaemia (AML) using an acute promyelocytic leukaemia (APL) experimental model (PML/RARα). Haematological analysis revealed that EGCG treatment reversed leucocytosis, anaemia and thrombocytopenia, and prolonged survival of PML/RARα mice. Read More

View Article and Full-Text PDF

Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk.

Mol Clin Oncol 2021 Jun 5;14(6):112. Epub 2021 Apr 5.

Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P.R. China.

In order to explore the optimal timing for initiating cytoreduction chemotherapy following all-trans retinoic acid plus arsenic trioxide administration, 58 newly diagnosed patients with acute promyelocytic leukemia (APL) with low-intermediate mortality risk were retrospectively analyzed. During induction treatment, white blood cell (WBC) count >4x10/l and multiplication rate of WBC <3 days were defined as rapid WBC multiplication. Patients were divided into two groups: With or without rapid WBC multiplication. Read More

View Article and Full-Text PDF

[Childhood acute promyelocytic leukemia complicated with thrombosis: four cases and literatures review].

Zhonghua Er Ke Za Zhi 2021 May;59(5):407-411

Department of Hematology and Oncology, Children's Hospital, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

To investigate the clinical characteristics and prognosis of children with acute promyelocytic leukemia (APL) complicated with thrombosis. The clinical profiles of four APL patients complicated with thrombosis treated at the First Affiliated Hospital of Zhengzhou University between January 2012 and December 2019 were reviewed. Literature search and review covered the China national knowledge infrastructure, Wanfang database, China biology medicine disc and PubMed using the key words of "acute promyelocytic leukemia" and "thrombosis" up to June 2020. Read More

View Article and Full-Text PDF

C/EBPα is indispensable for PML/RARα-mediated suppression of long non-coding RNA NEAT1 in acute promyelocytic leukemia cells.

Aging (Albany NY) 2021 Apr 26;13. Epub 2021 Apr 26.

Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Better understanding of the transcriptional regulatory network in acute promyelocytic leukemia (APL) cells is critical to illustrate the pathogenesis of other types of acute myeloid leukemia. Previous studies have primarily focused on the retinoic acid signaling pathway and how it is interfered with by promyelocytic leukemia/retinoic acid receptor-α (PML/RARα) fusion protein. However, this hardly explains how APL cells are blocked at the promyelocytic stage. Read More

View Article and Full-Text PDF

TRIB3 promotes proliferation, migration, and invasion of retinoblastoma cells by activating the AKT/mTOR signaling pathway.

Cancer Biomark 2021 Apr 21. Epub 2021 Apr 21.

Department of Fundus Disease, Huainan Chenguang Eye Hospital, Huainan, Anhui, China.

Background: Tribbles pseudokinase 3 (TRIB3) is a member of the tribbles-related family, which has been determined in various cancers, including renal cell carcinoma, acute promyelocytic leukemia, colorectal cancer, endometrial cancer, and glioma. However, its role in retinoblastoma (RB) has not yet been explored.

Methods: The expression level of TRIB3 was detected in RB tissues and cell lines using qRT-PCR. Read More

View Article and Full-Text PDF

All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks.

Expert Opin Drug Deliv 2021 Apr 26. Epub 2021 Apr 26.

Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Introduction: All- retinoic acid (ATRA, tretinoin) is the main drug used in the treatment of acute promyelocytic leukemia (APL). Despite its impressive activity against APL, the same could not be clinically observed in other types of cancer. Nanotechnology can be a tool to enhance ATRA anticancer efficacy and resolve its drawbacks in APL as well as in other malignancies. Read More

View Article and Full-Text PDF

Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia.

Eur J Med Chem 2021 Apr 15;220:113451. Epub 2021 Apr 15.

Medical College, Guizhou University, Guiyang, 550025, PR China. Electronic address:

All-trans-retinoic acid (ATRA) is effective for preventing cancer and treating skin diseases and acute promyelocytic leukaemia (APL). These pharmacological effects of ATRA are mainly mediated by retinoid X receptors (RXRs) and retinoic acid receptors (RARs). This article provides a comprehensive overview of the clinical progress on and the molecular mechanisms of ATRA in the treatment of APL. Read More

View Article and Full-Text PDF

Precision medicine in myeloid malignancies.

Semin Cancer Biol 2021 Apr 22. Epub 2021 Apr 22.

Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address:

Myeloid malignancies have always been at the forefront of an improved understanding of the molecular pathogenesis of cancer. In accordance, over the last years, basic research focusing on the aberrations underlying malignant transformation of myeloid cells has provided the basis for precision medicine approaches and subsequently has led to the development of powerful therapeutic strategies. In this review article, we will recapitulate what has happened since in the 1980s the use of all-trans retinoic acid (ATRA), as a first targeted cancer therapy, has changed one of the deadliest leukemia subtypes, acute promyelocytic leukemia (APL), into one that can be cured without classical chemotherapy today. Read More

View Article and Full-Text PDF

Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.

Ann Hematol 2021 Apr 24. Epub 2021 Apr 24.

Department of Central Laboratory, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, People's Republic of China.

Acute promyelocytic leukemia (APL) cells constitutively express a large amount of tissue factor (TF) antigen, most of which is present in the cytoplasm. Coagulopathy may persist after induction therapy. We evaluated the overall role of circulating microparticles (MPs) in coagulation activation in APL-associated coagulopathy before and during induction therapy. Read More

View Article and Full-Text PDF

Integration of genomic and transcriptomic markers improves the prognosis prediction of acute promyelocytic leukemia.

Clin Cancer Res 2021 Apr 23. Epub 2021 Apr 23.

Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Purpose: The current stratification system for acute promyelocytic leukemia (APL) is based on the white blood cell (WBC) and the platelet counts (i.e., Sanz score) over the past two decades. Read More

View Article and Full-Text PDF